December 19, 2004 -- Despite Pfizer’s Celebrex announcement, much of last week’s news was positive, and the Centient Biotech 200™ rose a very respectable 1.6%, far outpacing both the NYSE Comp and Nasdaq. We discuss that blockbuster story, plus the good news for drugs from Eyetech, OSI Pharma, Genentech, American Pharma Partners, and CancerVax. Even though big pharma came out of the week with a big black eye, we discuss a trend that bodes very well for biotech, very well indeed...
